<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro]]>
<![CDATA[FDA Launches Rare Disease Framework Initiative ]]>
FDA Opens Applications for New Pilot to Shorten Drug Approval Times: What Sponsors Need to Know
Earlier this month, FDA opened applications for a new Expedited Investigational New Drug (IND) Pilot Program (the “Program”), an initiative launched under HHS Operation TrialBlazer...
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study.
<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>
<![CDATA[FDA Grants Accelerated Approval to INOVIO’s Voceryq for RRP, Reducing Surgical Burden]]>
FDA unveils guidance for ‘plug and play’ gene therapies
The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same diseas...
FDA starts review of Roche’s multiple sclerosis pill
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
FDA grants priority review to ‘high-efficacy’ drug for 2 types of MS
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Roche seeking approval of its BTK inhibitor fenebrutinib as a treatment for relapsing forms of...
<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli]]>
FDA approves Atebrioz for fibrodysplasia ossificans progressiva
Editor’s note: This is a developing story. Please check back soon for updates.The FDA approved zilurgisertib tablets for the reduction of heterotopic ossification among patients ag...
<![CDATA[Pharmaceutical Executive Daily: FDA Approves Three New Therapies]]>
Grail multicancer detection test wins FDA advisers’ backing
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.
<![CDATA[Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.]]>
<![CDATA[FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Me...
<![CDATA[FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B]]>
<![CDATA[FDA Approves Pimjetmi for Patients With Tenosynovial Giant Cell Tumor]]>
Rare Disease Refresh: FDA’s Rare Disease Framework Initiative
By James E. Valentine & Charles G. Raver & Frank J. Sasinowski —
VB Spine Announces FDA Breakthrough Device Designation for New Blood Test Designed to Identify Patients at Risk for Scol...
VB Spine LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ScolimiR-3D.
<![CDATA[FDA Approves asundexian for Secondary Stroke Risk Reduction ]]>
<![CDATA[FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease]]>
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.